Denmark · Delayed Price · Currency is DKK TCM Group Earnings Call Transcripts
Fiscal Year 2025
-
Q4 2025 saw 10.5% revenue growth and improved gross margin, driven by both B2B and B2C segments and the Celebert acquisition. 2026 guidance anticipates further revenue and profit growth, with continued efficiency initiatives and a strong dividend proposal.
-
Q3 2025 saw 4.1% revenue growth and improved gross margin, driven by both B2B and B2C segments, with Denmark and Norway contributing. Full ownership of Celebat was acquired, and guidance for 2025 was narrowed. SG&A costs rose due to store acquisitions, but turnaround efforts are ongoing.
-
Q2 2025 saw 5% revenue growth and a 20% rise in adjusted EBIT, with improved gross margin and strong cash flow. Guidance for 2025 was narrowed due to muted consumer activity in late Q2, while the acquisition of Celebert and investments in digitalization support future growth.
-
Revenue grew 5% in Q1 2025, led by B2C and Norwegian market recovery, with improved gross margin and adjusted EBIT. Guidance for 2025 is maintained amid geopolitical uncertainty, with both B2B and B2C segments needing to stay strong to meet targets.
Fiscal Year 2024
-
Q4 saw a 2% sales decline due to weak B2B, but B2C grew over 5% and order intake was strong. Gross margin and EBIT improved, with full-year results at the top end of guidance. 2025 outlook is cautiously optimistic, with margin pressure from costs and low B2B visibility.
-
Q3 saw 7% organic sales growth, led by strong B2C performance, while B2B/project sales declined. Gross margin and EBIT improved year-over-year, and full-year guidance was narrowed, with a positive outlook for B2C and continued B2B weakness.
-
Q2 delivered 5% organic sales growth and a 30% revenue increase, driven by strong B2C performance and the Aubo acquisition. B2B remains weak, but full-year guidance was raised, with B2C now at a record share of sales.